Search results
Results from the WOW.Com Content Network
Find the latest Cardiff Oncology, Inc. (CRDF) stock quote, history, news and other vital information to help you with your stock trading and investing.
Get the latest Cardiff Oncology, Inc. (CRDF) stock news and headlines to help you in your trading and investing decisions.
Discover historical prices for CRDF stock on Yahoo Finance. View daily, weekly or monthly format back to when Cardiff Oncology, Inc. stock was issued.
See Cardiff Oncology, Inc. (CRDF) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Find the latest Cardiff Oncology, Inc. (CRDF) stock quote, history, news and other vital information to help you with your stock trading and investing.
Find the latest Cardiff Oncology, Inc. (CRDF) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
Find out all the key statistics for Cardiff Oncology, Inc. (CRDF), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
Interim topline results from CRDF-004 are expected in mid-2024. Contingent upon the results, Cardiff Oncology will initiate a Phase 3, randomized trial, CRDF-005, with registrational intent.